Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure

American Journal of Physiology - Endocrinology and Metabolism

Volumn 271, Issue 1 34-1, 1996, Pages

  Vaziri, N D ^a,b   Zhou, X J ^a   Naqvi, F ^a   Smith, J ^a   Oveisi, F ^a   Wang, Z Q ^a   Purdy, R E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anemia; cytosolic calcium; cytosolic magnesium; guanosine 3',5' cyclic monophosphate; sodium nitroprusside; vascular relaxation

Indexed keywords

ANGIOTENSIN; CALCIUM ION; CYCLIC GMP; METHOXAMINE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POTASSIUM ION; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; HEMATOCRIT; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 0029810419     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.1996.271.1.e113     Document Type: Article

References (33)

1. Abraham, P. A., and M. G. Macres. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J. Am. Soc. Nephrol. 2: 927-936, 1991.
2. Altura, B. M., and B. T. Altura. Role of magnesium in the pathogenesis of hypertension: relationship to its actions on cardiac and vascular smooth muscle. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by J. H. Laragh and B. M. Brenner. New York: Raven, 1990, p. 1003-1025.
3. Brunet, P., A. M. Lorec, F. Leonetti, C. Roubicek, K. Jaber, F. Roux, and Y. Beland. Plasma endothelin in hemodialysis patients treated with recombinant human erythropoietin. Nephrol. Dial. Transplant. 9: 650-654, 1994.
4. Buckner, F. S., J. W. Eschbach, N. R. Haley, R. C. Davidson, and J. W. Adamson. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am. J. Hypertens. 3: 947-955, 1990.
5. Carlini, R., C. I. Obialo, and M. Rothstein. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 6: 103-107, 1993.
6. Edmunds, M., and J. Walls. Blood pressure and erythropoietin. Lancet 1: 351-352, 1988.
7. Eggena, P., P. Willsey, N. Jamgotchian, L. Truckenbrod, M. S. Hu, J. D. Barrett, M. P. Eggena, K. Clegg, F. Nakhoul, and D. B. N. Lee. Influence of recombinant human erythropoietin on blood pressure and renin-angiotensin systems. Am. J. Physiol. 261 (Endocrinol. Metab. 24): E642-E646, 1991.
8. Heidenreich, S., K. H. Rahn, and W. Zidek. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39: 259-265, 1991.
9. Hon, G. G., N. D. Vaziri, C. J. Kaupke, A. Tehranzadeh, and C. H. Barton. Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif. Organs 19: 188-191, 1995.
10. Ignarro, L. J, and P. J. Kadowitz. The pharmacological and physiological role of cGMP in vascular smooth muscle relaxation. Annu. Rev. Pharmacol. Toxicol. 25: 171-191, 1985.
11. Karaki, H. Calcium localization and sensitivity in vascular smooth muscle. Trends Pharmacol. Sci. 10: 320-325, 1989.
12. Kaupke, C. J., G. C. Butler, and N. D. Vaziri. Effect of erythropoietin on platelet production in dialysis patients. J. Am. Soc. Nephrol. 3: 1672-1679, 1993.
13. Kaupke, C. J., S. Kim, and N. D. Vaziri. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J. Am. Soc. Nephrol. 4: 1874-1878, 1994.
14. Kaupke, C. J., X. J. Zhou, and N. D. Vaziri. Cytosolic ionized magnesium concentration in end-stage renal disease: effect of hemodialysis. Am. Soc. Artif. Intern. Organs J. 39: M614-M617, 1993.
15. Krzesinski, J., F. Du, M. Pequeux, and G. Rorive. Plasma Na-K ATP inhibitor activity and intracellular ions during hemodialysis. Int. J. Artif. Organs 16: 23-30, 1993.
16. Lai, K. N., S. F. Lui, J. C. K. Leung, E. Law, and M. G. Nicholls. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and plasma vasoactive hormones in patients on continuous ambulatory peritoneal dialysis Nephron 57: 394-400, 1991.
17. Lincoln, T. M., and T. L. Cornwell. Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 28: 129-137, 1991.
18. Martin, J., and S. Moncada. Blood pressure, erythropoietin and nitric oxide. Lancet 1: 644, 1988.
19. Matuura, T., M. Kohno, Y. Kanayama, K. Yasunari, K. Murakawa, T. Takeda, K. Ishimori, I. Morishima, and T. Yonezawa. Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. Biochem. Biophys. Res. Commun 143: 1012-1017, 1987.
20. Moia, M., P. M. Mannucci, L. Vizzotto, S. Casati, M. Cattaneo, and C. Ponticelli. Improvement in the hemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2: 1227-1229, 1987.
21. Morgan, K. G., P. Papageorgiou, and M. J. Jiang. Pathophysiologic role of calcium in the development of vascular smooth muscle tone. Am. J. Cardiol. 64: 35F-40F, 1989.
22. Murad, F. Cyclic guanosine monophosphate as a mediator of vasodilatation. J. Clin. Invest. 78: 1-5, 1986.
23. Neff, M. S., K. E. Kim, M. Persoff, G. Onesti, and C. Swartz. Hemodynamics of uremic anemia. Circulation 43: 876-883, 1971.
24. Pollock, M., J. Bommer, H. J. Gurland, K. M. Koch, W. Schoeppe, P. Scigalla, and C. A. Baldamus. Effect of recombinant human erythropoietin treatment in end-stage renal failure patients. Contrib. Nephrol. 76: 201-211, 1989.
25. Raine, A. E. G. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy Lancet 1: 97-99, 1988.
26. Raine, A. E. G., and S. D. Roger. Effects of erythropoietin on BP. Am. J. Kidney Dis. 18: 76-83, 1991.
27. Raju, B., E. Murphy, L. A. Levy, R. D. Hall, and R. E. London. A fluorescent indicator for measuring cytosolic free magnesium. Am. J. Physiol. 256 (Cell Physiol. 25): C540-C548, 1989.
28. Resnick, L. M. Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders. Am. J. Med. 93, Suppl. 2A: 11S-20S, 1992.
29. Steffen, H. M., R. Brunner, R. Muller, S. Dengenhardt, M. Pollok, R. Lang, and C. A. Baldamus. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib. Nephrol. 76: 292-298, 1989
30. Van Geet, C., R. Van Damme-Lombaerts, M. Vanrusselt, and A. de Mol. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilization in uremic children: a possible link. Thromb. Haemostasis 64: 7-10, 1990.
31. Vasdev, S., P. Thompson, C. Triggle, P. Fernandez, P. Bolli, and V. S. Ananthanarayanan. Fura-2 used as a probe to show elevated intracellular free calcium in platelets of DAHL-sensitive rats fed a high salt diet. Biochem. Biophys. Res. Commun. 154: 380-386, 1988.
32. Vaziri, N. D., X. J. Zhou, J. Smith, F. Oveisi, K. Baldwin, and R. E. Purdy. In vivo and in vitro pressor effects of erythropoietin. Am. J. Physiol. 269 (Renal Fluid Electrolyte Physiol. 38): F838-F845, 1995.
33. Zehnder, C., Z. Gluck, C. Descoeudres, D. E. Uehlinger, and A. Blumberg. Human recombinant erythropoietin in anemic patients on maintenance hemodialysis: secondary effects of the increase of hemoglobin. Nephrol. Dial. Transplant. 3: 657-660, 1988.